Webinar Date/Time: Tuesday, August 27, 2024 at 11:00 AM EDT | 8:00 AM PDT | 4:00 PM BST | 5:00 PM CEST
Join experts to explore regulatory strategies, clinical challenges, and operational models that speed up trials and bring patient treatments.
Register Free: https://www.appliedclinicaltrialsonline.com/act_w/design-to-delivery
Event overview
Explore how groundbreaking cell and gene therapies (CAGTs) are revolutionizing previously untreatable diseases to improve the quality of life for patients. Join experts from IQVIA Biotech and IQVIA as they address the current state of CAGTs, regulatory strategies that move innovation forward and critical clinical development decisions.
Learning Objectives
Speakers:
Erin Finot, MS, MBA
Vice President, Immuno-Oncology and CAGT
IQVIA Biotech
Erin Finot, MS, MBA, is vice president of immuno-oncology and CAGT at IQVIA Biotech. She leads strategic efforts to ensure high-quality services and innovative trial solutions for biotech sponsors. With over 20 years of experience in global clinical research and drug development, Erin's therapeutic expertise guides sponsors through the dynamic landscape of immuno-oncology and cell and gene therapies.
Diego Correa, MD, PhD, MSc
Vice President and Global Head, Cell and Gene Therapy Center of Excellence
IQVIA
Diego Correa, MD, PhD, MSc, is vice president and global head of the Cell and Gene Therapy Center of Excellence at IQVIA. He has more than two decades of research experience in cell therapy, tissue engineering, and regenerative medicine. His expertise guides clinical trial sponsors and study teams toward innovative, data-driven solutions for CAGT studies. Dr. Correa has 60-plus peer-reviewed publications and actively contributes to international scientific organizations.
Patrick Brady, PharmD
Global Head, Therapeutic Innovation and Regulatory Science
IQVIA
Patrick Brady, PharmD, is global head of therapeutic innovation and regulatory science at IQVIA. With more than two decades of experience in regulatory affairs in the biopharmaceutical industry, Dr. Brady regularly advises R&D leadership and project teams on global drug development strategies, emerging technologies, and the changing regulatory landscape and policies to help inform strategies and decision-making.
Register Free: https://www.appliedclinicaltrialsonline.com/act_w/design-to-delivery
What Can ClinOps Learn from Pre-Clinical?
August 10th 2021Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.
Moving Towards Decentralized Elements: Q&A with Scott Palmese, Worldwide Clinical Trials
December 6th 2024Palmese, executive director, site relationships and DCT solutions, discusses the practice of incorporating decentralized elements in a study rather than planning a decentralized trial from the start.
Phase III MOVe-NOW Trial to Evaluate New Lagevrio Formulation Targeting High-Risk COVID-19 Patients
December 6th 2024Merck and Ridgeback Biotherapeutics have launched the Phase III MOVe-NOW trial to evaluate a new, streamlined formulation of Lagevrio (molnupiravir) for treating non-hospitalized COVID-19 patients at high risk of severe disease progression who are unable to use other antiviral therapies.
Phase II Piranga Trial Shows Promise of Xalnesiran Combination for Hepatitis B Treatment
December 5th 2024Phase II Piranga trial found that the combination of xalnesiran and an immunomodulator effectively reduced hepatitis B surface antigen (HBsAg) levels, but highlighted challenges in response durability and efficacy in patients with high HBsAg levels.